Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)

Facial and neck erythema associated with dupilumab treatment: A systematic review

(2021) Christine E. Jo et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

(2021) Thomas Bieber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence of Conjunctivitis and Other Ocular Surface Disorders in Patients with Long-Term Dupilumab Use

(2020) Christine E. Jo et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients

(2020) Maria L. Espinosa et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

(2020) Eric L Simpson et al.   LANCET

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

(2020) Jonathan I. Silverberg et al.   JAMA Dermatology

Quantifying Patient Preferences for Systemic Atopic Dermatitis Treatments Using a Discrete-Choice Experiment

(2020) Marco Boeri et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort

(2020) L. Jaulent et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement

(2019) Y.A. Leshem et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis

(2019) G. Yosipovitch et al.   BRITISH JOURNAL OF DERMATOLOGY

Assessment of the Development of New Regional Dermatoses in Patients Treated for Atopic Dermatitis With Dupilumab

(2019) Gefei Alex Zhu et al.   JAMA Dermatology

Acute arthritis and arthralgia as an adverse drug reaction to dupilumab: a case report

(2019) L.E.M de Wijs et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Patient and physician preferences for atopic dermatitis injection treatments in Japan

(2019) Yukari Okubo et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Characterizing dupilumab facial redness: A multi-institution retrospective medical record review

(2019) Reid A. Waldman et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Placebo-responses in randomized controlled trials for systemic therapy in atopic dermatitis: a systematic review and meta-analysis

(2019) Harrison H. Lee et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis With Dupilumab

(2019) Angèle Soria et al.   JAMA Dermatology

Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases

(2019) Kata P. Szilveszter et al.   Frontiers in Immunology

Recent developments and advances in atopic dermatitis and food allergy

(2019) Kazunari Sugita et al.   ALLERGOLOGY INTERNATIONAL

Targeting the Janus Kinase Family in Autoimmune Skin Diseases

(2019) Michael D. Howell et al.   Frontiers in Immunology

Placebo response in phase 2 and 3 trials of systemic and biological therapies for atopic dermatitis—a systematic review and meta‐analysis

(2019) T.H. Andreasen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Emerging Topical and Systemic JAK Inhibitors in Dermatology

(2019) Farzan Solimani et al.   Frontiers in Immunology

Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape

(2018) Mark Boguniewicz et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases

(2018) Michael L. Vazquez et al.   JOURNAL OF MEDICINAL CHEMISTRY

Atopic dermatitis

(2018) Stephan Weidinger et al.   Nature Reviews Disease Primers

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

(2017) Andrew Blauvelt et al.   LANCET

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

(2016) Eric L. Simpson et al.   NEW ENGLAND JOURNAL OF MEDICINE